The US has approved the first treatment to redesign a patient’s own immune system so it attacks cancer. The regulator – the US Food and Drug Administration – said its decision was a “historic” moment and medicine was now “entering a new frontier”. The company Novartis is charging $475,000 (£367,000) for the “living drug” therapy, which leaves 83% of people …

A trial to extend the lifespan of pet dogs has shown promise – with marked improvement in heart health. Anti-rejection medicine rapamycin was given to dogs in phase one trials by evolutionary geneticists at the University of Washington, the Daily Telegraph reports. It is usually given to humans who’ve had a kidney transplant, but was found to extend the life …